Ftse Mib
34.433,22
-0,08%
DAX
18.692,83
0,06%
S&P 500
5.307,01
-0,27%
NASDAQ
16.801,54
-0,18%
Bitcoin
69.764,07
0,96%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Dermata Therapeutics Inc (DRMA) Dermata Therapeutics Inc (DRMA) Notizie

DRMA

Dermata Therapeutics (DRMA)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:DRMA
DataOraFonteTitoloSimboloCompagnia
12/01/202422:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DRMADermata Therapeutics Inc
06/01/202403:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DRMADermata Therapeutics Inc
18/12/202306:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:DRMADermata Therapeutics Inc
15/12/202323:00Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:DRMADermata Therapeutics Inc
08/12/202323:29Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:DRMADermata Therapeutics Inc
07/12/202322:05Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:DRMADermata Therapeutics Inc
29/11/202323:16Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:DRMADermata Therapeutics Inc
09/11/202322:09Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DRMADermata Therapeutics Inc
14/09/202322:32Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:DRMADermata Therapeutics Inc
27/07/202322:50Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:DRMADermata Therapeutics Inc
12/07/202315:02Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:DRMADermata Therapeutics Inc
07/07/202322:21Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:DRMADermata Therapeutics Inc
23/06/202322:29Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:DRMADermata Therapeutics Inc
23/06/202322:19Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:DRMADermata Therapeutics Inc
12/06/202323:28Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)NASDAQ:DRMADermata Therapeutics Inc
24/05/202323:14Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:DRMADermata Therapeutics Inc
11/05/202322:08Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:DRMADermata Therapeutics Inc
31/03/202322:11Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:DRMADermata Therapeutics Inc
21/03/202311:01Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:DRMADermata Therapeutics Inc
20/03/202314:01Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(4) (424b4)NASDAQ:DRMADermata Therapeutics Inc
17/03/202311:04Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:DRMADermata Therapeutics Inc
13/03/202322:08Edgar (US Regulatory)Securities Registration Statement (s-1/a)NASDAQ:DRMADermata Therapeutics Inc
21/02/202322:10Edgar (US Regulatory)Annual Report (10-k)NASDAQ:DRMADermata Therapeutics Inc
05/01/202322:07Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:DRMADermata Therapeutics Inc
17/11/202213:25TipRanksMaxim Group Reaffirms Their Buy Rating on Dermata Therapeutics (DRMA)NASDAQ:DRMADermata Therapeutics Inc
16/11/202219:15AllPennyStocks.comMicro Cap Files For $100 Million Shelf RegistrationNASDAQ:DRMADermata Therapeutics Inc
15/11/202222:07Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:DRMADermata Therapeutics Inc
19/08/202220:25TipRanksMaxim Group Sticks to Its Buy Rating for Dermata Therapeutics (DRMA)NASDAQ:DRMADermata Therapeutics Inc
20/05/202222:06Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:DRMADermata Therapeutics Inc
18/05/202221:05TipRanksDermata Therapeutics (DRMA) Has a New Rating from Maxim GroupNASDAQ:DRMADermata Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:DRMA

La tua Cronologia

BIT
CNS
Civitanavi Systems
BIT
S27172
Societe Generale Effekten
BOV
LOGG3
LOG Commercial ON
LSE
KITW
Kitwave
TG
ADB
Adobe
LSE
80WZ
Res.mtg 16 M1ba
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network